Typically treatment for a variety of eye probems are problematic due to the fact that medication remain on the eye surface for only 1-2 minutes. Having close ties to theUniversity of Pittsburh, Ankybio LLC has developed a capability and procedure that enables eye-drop administered therapeutics to remain active on the eyeball surface 3-5 days. Localized to application site, the developed technology not ony extends duration of action but also reduces dosage requirements minimizes systemetic toxity.
